Drug General Information
Drug ID	D0E5XA
Former ID	DCL000210
Drug Name	R763
Indication	Haematological malignancies [ICD9: 200-209; ICD10:C81-C86]		Phase 1	[549926]
Therapeutic Class	Anticancer Agents
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Aurora kinase B	Target Info	Inhibitor	[537610]
	Aurora kinase A	Target Info	Inhibitor	[537610]
KEGG Pathway	Oocyte meiosis
Pathway Interaction Database	Aurora B signaling
	Signaling by Aurora kinases
	Aurora C signaling
	FOXM1 transcription factor network
	Aurora A signalingaurora_b_pathway:Aurora B signaling
	Integrin-linked kinase signaling
	PLK1 signaling events
	Aurora A signaling
Reactome	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
	Separation of Sister Chromatids
	Resolution of Sister Chromatid Cohesion
	RHO GTPases Activate Formins
	Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
	Regulation of PLK1 Activity at G2/M Transition
WikiPathways	Mitotic Metaphase and Anaphase
	Mitotic Prometaphase
	Regulation of Microtubule Cytoskeleton
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
	JAK/STAT
	Gastric Cancer Network 1
	Integrated Breast Cancer Pathway
	APC/C-mediated degradation of cell cycle proteins
References
Ref 549926	Clinical pipeline report, company report or official report of Rigel.
Ref 537610	Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2009 Jul 17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.